Sabrina Niedermoser1, Joshua Chin2, Carmen Wängler3, Alexey Kostikov2, Vadim Bernard-Gauthier4, Nils Vogler5, Jean-Paul Soucy6, Alexander J McEwan7, Ralf Schirrmacher4, Björn Wängler1. 1. Division of Molecular Imaging and Radiochemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany. 2. McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada. 3. Division of Biomedical Chemistry, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany schirrma@ualberta.ca Bjoern.Waengler@medma.uni-heidelberg.de. 4. McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada Division of Oncological Imaging, Department of Oncology, University of Alberta, Edmonton, AB, Canada. 5. Division of Nuclear Medicine, Department of Clinical Radiology and Nuclear Medicine, Medical Faculty Mannheim of Heidelberg University, Mannheim, Germany; and. 6. McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Canada Concordia-PERFORM Centre, Concordia University, Montreal, Canada. 7. Division of Oncological Imaging, Department of Oncology, University of Alberta, Edmonton, AB, Canada.
Abstract
UNLABELLED: Radiolabeled peptides for tumor imaging with PET that can be produced with kits are currently in the spotlight of radiopharmacy and nuclear medicine. The diagnosis of neuroendocrine tumors in particular has been a prime example for the usefulness of peptides labeled with a variety of different radionuclides. Among those, (68)Ga and (18)F stand out because of the ease of radionuclide introduction (e.g., (68)Ga isotope) or optimal nuclide properties for PET imaging (slightly favoring the (18)F isotope). The in vivo properties of good manufacturing practice-compliant, newly developed kitlike-producible (18)F-SiFA- and (18)F-SiFAlin- (SiFA = silicon-fluoride acceptor) modified TATE derivatives were compared with the current clinical gold standard (68)Ga-DOTATATE for high-quality imaging of somatostatin receptor-bearing tumors. METHODS: SiFA- and SiFAlin-derivatized somatostatin analogs were synthesized and radiolabeled using cartridge-based dried (18)F and purified via a C18 cartridge (radiochemical yield 49.8% ± 5.9% within 20-25 min) without high-performance liquid chromatography purification. Tracer lipophilicity and stability in human serum were tested in vitro. Competitive receptor binding affinity studies were performed using AR42J cells. The most promising tracers were evaluated in vivo in an AR42J xenograft mouse model by ex vivo biodistribution and in vivo PET/CT imaging studies for evaluation of their pharmacokinetic profiles, and the results were compared with those of the current clinical gold standard (68)Ga-DOTATATE. RESULTS: Synthetically easily accessible (18)F-labeled silicon-fluoride acceptor-modified somatostatin analogs were developed. They exhibited high binding affinities to somatostatin receptor-positive tumor cells (1.88-14.82 nM). The most potent compound demonstrated comparable pharmacokinetics and an even slightly higher absolute tumor accumulation level in ex vivo biodistribution studies as well as higher tumor standardized uptake values in PET/CT imaging than (68)Ga-DOTATATE in vivo. The radioactivity uptake in nontumor tissue was higher than for (68)Ga-DOTATATE. CONCLUSION: The introduction of the novel SiFA building block SiFAlin and of hydrophilic auxiliaries enables a favorable in vivo biodistribution profile of the modified TATE peptides, resulting in high tumor-to-background ratios although lower than those observed with (68)Ga-DOTATATE. As further advantage, the SiFA methodology enables a kitlike labeling procedure for (18)F-labeled peptides advantageous for routine clinical application.
UNLABELLED: Radiolabeled peptides for tumor imaging with PET that can be produced with kits are currently in the spotlight of radiopharmacy and nuclear medicine. The diagnosis of neuroendocrine tumors in particular has been a prime example for the usefulness of peptides labeled with a variety of different radionuclides. Among those, (68)Ga and (18)F stand out because of the ease of radionuclide introduction (e.g., (68)Ga isotope) or optimal nuclide properties for PET imaging (slightly favoring the (18)F isotope). The in vivo properties of good manufacturing practice-compliant, newly developed kitlike-producible (18)F-SiFA- and (18)F-SiFAlin- (SiFA = silicon-fluoride acceptor) modified TATE derivatives were compared with the current clinical gold standard (68)Ga-DOTATATE for high-quality imaging of somatostatin receptor-bearing tumors. METHODS:SiFA- and SiFAlin-derivatized somatostatin analogs were synthesized and radiolabeled using cartridge-based dried (18)F and purified via a C18 cartridge (radiochemical yield 49.8% ± 5.9% within 20-25 min) without high-performance liquid chromatography purification. Tracer lipophilicity and stability in human serum were tested in vitro. Competitive receptor binding affinity studies were performed using AR42J cells. The most promising tracers were evaluated in vivo in an AR42J xenograft mouse model by ex vivo biodistribution and in vivo PET/CT imaging studies for evaluation of their pharmacokinetic profiles, and the results were compared with those of the current clinical gold standard (68)Ga-DOTATATE. RESULTS: Synthetically easily accessible (18)F-labeled silicon-fluoride acceptor-modified somatostatin analogs were developed. They exhibited high binding affinities to somatostatin receptor-positive tumor cells (1.88-14.82 nM). The most potent compound demonstrated comparable pharmacokinetics and an even slightly higher absolute tumor accumulation level in ex vivo biodistribution studies as well as higher tumor standardized uptake values in PET/CT imaging than (68)Ga-DOTATATE in vivo. The radioactivity uptake in nontumor tissue was higher than for (68)Ga-DOTATATE. CONCLUSION: The introduction of the novel SiFA building block SiFAlin and of hydrophilic auxiliaries enables a favorable in vivo biodistribution profile of the modified TATE peptides, resulting in high tumor-to-background ratios although lower than those observed with (68)Ga-DOTATATE. As further advantage, the SiFA methodology enables a kitlike labeling procedure for (18)F-labeled peptides advantageous for routine clinical application.
Authors: Harun Ilhan; A Todica; S Lindner; G Boening; A Gosewisch; C Wängler; B Wängler; R Schirrmacher; P Bartenstein Journal: Eur J Nucl Med Mol Imaging Date: 2019-07-27 Impact factor: 9.236
Authors: Xiaoyun Deng; Jian Rong; Lu Wang; Neil Vasdev; Lei Zhang; Lee Josephson; Steven H Liang Journal: Angew Chem Int Ed Engl Date: 2019-01-14 Impact factor: 15.336
Authors: Harun Ilhan; S Lindner; A Todica; C C Cyran; R Tiling; C J Auernhammer; C Spitzweg; S Boeck; M Unterrainer; F J Gildehaus; G Böning; K Jurkschat; C Wängler; B Wängler; R Schirrmacher; P Bartenstein Journal: Eur J Nucl Med Mol Imaging Date: 2019-09-06 Impact factor: 9.236
Authors: Ksenia Lisova; Maxim Sergeev; Susan Evans-Axelsson; Andreea D Stuparu; Seval Beykan; Jeffrey Collins; Jason Jones; Michael Lassmann; Ken Herrmann; David Perrin; Jason T Lee; Roger Slavik; R Michael van Dam Journal: Nucl Med Biol Date: 2018-04-20 Impact factor: 2.408
Authors: Simon Lindner; Carmen Wängler; Björn Wängler; Ralf Schirrmacher; Justin J Bailey; Klaus Jurkschat; Peter Bartenstein Journal: Nat Protoc Date: 2020-11-23 Impact factor: 13.491
Authors: Xia Cheng; Ralph Hübner; Valeska von Kiedrowski; Gert Fricker; Ralf Schirrmacher; Carmen Wängler; Björn Wängler Journal: Pharmaceuticals (Basel) Date: 2021-06-07